# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy and maintains $4 price target.
BioCardia, Inc. (NASDAQ:BCDA), a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular...
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12036371).pn
CellProthera's clinical results from the Phase I/IIb EXCELLENT Trial, which studied the feasibility of transendocardial inj...
On Friday before the market open, BioCardia announced it received approval from the United States Patent Office for its applic...